Phenotypically aggressive schwannomas show significant association between percent PD-L1 positivity, tumor progression, and unfavorable House-Brackmann facial nerve function highlighting the PD-1/PD-L1 axis as a promising target for future immunotherapeutics [79]. This evidence concerns the gene PDCD1 and neoplasm.